Boehringer Ingelheim investigational lung cancer treatment

CNW Group 2012-06-11

Views 45

Boehringer Ingelheim's investigational lung cancer treatment afatinib* prolongs progression free survival (PFS) for advanced non-small cell lung cancer patients with specific EGFR genetic mutations.

http://cnw.ca/aYV1E

Share This Video


Download

  
Report form